These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19528803)

  • 1. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C; Alasker A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    Bhojani N; Jeldres C; Patard JJ; Perrotte P; Suardi N; Hutterer G; Patenaude F; Oudard S; Karakiewicz PI
    Eur Urol; 2008 May; 53(5):917-30. PubMed ID: 18054825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Mulder SF; van Spronsen DJ; De Mulder PH
    Onkologie; 2007 May; 30(5):260-4. PubMed ID: 17460422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 13. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 17. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
    Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
    Procopio G; Verzoni E; Iacovelli R; Colecchia M; Torelli T; Mariani L
    Clin Exp Nephrol; 2012 Jun; 16(3):464-7. PubMed ID: 22278601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.